Share on StockTwits

PharMerica (NYSE:PMC) Director Robert A. Oakley sold 8,399 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $26.55, for a total value of $222,993.45. Following the completion of the transaction, the director now directly owns 43,561 shares in the company, valued at approximately $1,156,545. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of PharMerica (NYSE:PMC) traded down 2.45% during mid-day trading on Tuesday, hitting $26.31. The stock had a trading volume of 363,431 shares. PharMerica has a 1-year low of $11.84 and a 1-year high of $30.48. The stock has a 50-day moving average of $27.64 and a 200-day moving average of $26.80. The company’s market cap is $790.9 million.

PharMerica (NYSE:PMC) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.36 by $0.04. The company had revenue of $448.60 million for the quarter, compared to the consensus estimate of $432.70 million. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. On average, analysts predict that PharMerica will post $1.51 earnings per share for the current fiscal year.

PMC has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of PharMerica from a “neutral” rating to an “outperform” rating in a research note on Friday. They now have a $31.40 price target on the stock. Separately, analysts at Barclays initiated coverage on shares of PharMerica in a research note on Thursday, July 17th. They set an “underweight” rating on the stock. Finally, analysts at ISI Group reiterated a “positive” rating on shares of PharMerica in a research note on Wednesday, July 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. PharMerica presently has an average rating of “Buy” and an average target price of $27.08.

PharMerica Corporation is an institutional pharmacy services company, which services healthcare facilities and provides management pharmacy services to hospitals.

Receive News & Ratings for PharMerica Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co and related companies with Analyst Ratings Network's FREE daily email newsletter.